###### Strengths and limitations of this study

-   To the best of our knowledge, this is the first study to leverage randomised trial data to evaluate the cost-effectiveness of community-based self-collected HPV testing that is performed at women's homes or places of work.

-   The use of community health workers has the potential to reduce demands on overburdened healthcare providers.

-   Costs of the Advances in Screening and Prevention of Reproductive Cancers trial are retrospective as the trial was not designed to evaluate cost-effectiveness. Therefore, costs may reflect study as opposed to real-world conditions.

-   We also did not consider human resource and capacity constraints in the Ugandan healthcare system.

Introduction {#s1}
============

High-income countries have significantly reduced cervical cancer incidence and mortality by implementing organised cytology-based screening programmes.[@R1] The introduction of the prophylactic HPV vaccine has the potential to further reduce incidence and mortality of cervical and other HPV-related cancers. Despite these advances, cervical cancer remains a major cause of morbidity and mortality in low- and middle-income countries (LMICs) due to the absence of effective, organised screening programmes. In Uganda, cervical cancer is the top cause of cancer death in women.[@R2] In 2012, Uganda introduced a publicly funded national HPV vaccination programme in parts of the country.[@R3] However, due to low vaccine coverage and the targeting of adolescent girls before sexual debut,[@R3] screening continues to be the only form of prevention for most women.

There are significant barriers to access, implementation and quality assurance for cytology-based screening in LMICs. A systematic review of cost-effectiveness analyses in LMICs found that cytology is not an efficient screening test in low-resource settings.[@R4] The WHO no longer recommends cytology-based screening in LMICs that have not already achieved high coverage and quality assurance.[@R5] Instead, visual inspection with acetic acid (VIA) and HPV DNA testing have been proposed as alternatives that may be better suited to low-income settings. While VIA is inexpensive, provides same-visit results and allows for immediate treatment, test performance varies widely across providers, populations and settings.[@R6] Currently, WHO recommends HPV testing if resources permit.[@R5] HPV testing can be administered using provider-collected or self-collected sampling. While provider collection (of cervical samples) has been demonstrated to have higher sensitivity to detect precancer,[@R6] self-collection (of vaginal samples) has been shown to reduce patient barriers to screening[@R7] and may increase effectiveness and cost-effectiveness when it increases population coverage.[@R4]

While several studies have evaluated the cost-effectiveness of self-collected HPV testing in LMICs,[@R4] we could not identify any that evaluate the cost-effectiveness of a delivery model where self-collected HPV tests are offered at women's homes and/or places of work. In addition, we could not identify any studies that leveraged randomised trial data to test the hypothesis that the increased uptake associated with self-collection is cost-effective relative to clinic-based screening. Therefore, our objective with this study was to evaluate the cost-effectiveness of a randomised trial run by the Advances in Screening and Prevention of Reproductive Cancers (ASPIRE) Project, which compared community-based self-collected HPV testing to clinic-based VIA in Uganda.[@R11]

Methods {#s2}
=======

Analytical framework {#s2a}
--------------------

We used a previously developed Monte Carlo simulation model of HPV infection and cervical cancer that was calibrated to epidemiological data from Uganda[@R10] to project the lifetime health and economic outcomes associated with self-collected HPV testing versus clinic-based VIA. The model was informed by screening uptake, follow-up and retrospective costing data from the ASPIRE trial, conducted in Kisenyi, Uganda.[@R11]

The primary outcomes were the incremental cost-effectiveness ratio (ICER) and per cent reduction in lifetime cervical cancer risk (ie, cumulative lifetime cervical cancer incidence). ICERs are defined as the marginal cost (discounted per women cost) divided by the marginal benefit (discounted life expectancy) of a screening strategy compared with the next most costly strategy, after eliminating strategies that are dominated (defined as either more costly and less effective or having a higher ICER than more effective strategies). ICERs are expressed in 2014 US\$ per year of life saved (\$/YLS). We considered screening strategies with an ICER below US\$730,[@R14] the GDP per capita of Uganda in 2014, to be very cost-effective.[@R15] In keeping with guidelines on cost-effectiveness analysis, we discounted all costs and future life years at a rate of 3% per year and evaluated costs from a societal perspective, including costs irrespective of the payer.[@R16]

The ASPIRE trial {#s2b}
----------------

The ASPIRE trial was conducted in the Kisenyi district of Kampala, Uganda. For the trial, community health workers (CHWs) recruited 500 women at their homes or places of work who were between the ages of 30 and 65, lived and/or worked in Kisenyi, and had access to a mobile phone.[@R11] At the time of enrolment, consenting women were randomised into either HPV self-collection with VIA triage for HPV-positive women ('HPV-VIA') or VIA screen and treat ('VIA'). Women randomised to the HPV-VIA arm received instructions from a CHW on self-collection and were given the opportunity to self-collect HPV, *Neisseria gonorrhoea* and *Chlamydia trachomatis* (NGCT) samples. CHWs would then transport the samples to local laboratories in Kampala, Uganda where they were tested for HPV and NGCT. The CHWs contacted women by phone with their results. If HPV-positive, women were scheduled for a VIA triage test by a midwife at Kisenyi Health Unit. If VIA-positive, the women were offered immediate cryotherapy (if eligible for cryotherapy) or sent to a tertiary care centre for further diagnosis and treatment (if ineligible for cryotherapy for reasons such as lesion size, inability to adequately visualise the cervix or suspicion of cancer).

Women randomised to the VIA arm were scheduled for an appointment at the Kisenyi health unit. The CHWs contacted women in this arm by phone to remind them of their VIA appointment. When the VIA was performed, women were also offered provider-collected NGCT testing. Like the HPV-VIA arm, women who had a positive VIA screen were offered immediate cryotherapy (if eligible) or referred to a tertiary care centre for further evaluation and treatment.

Mathematical simulation model {#s2c}
-----------------------------

The individual-based microsimulation model of cervical cancer has been previously described, but we summarise key features here.[@R10] The model was programmed in C++. Girls enter the model at age 9, and each month face probabilities of transitioning between mutually exclusive health states including HPV infection (stratified by HPV genotype), cervical intraepithelial neoplasia grade 2 (CIN2), CIN3, cervical cancer (local, regional or distant stage) and death ([figure 1](#F1){ref-type="fig"}). Transitions between health states may be determined by age, HPV type, duration of HPV infection, duration of CIN, history of previous infection and patterns of screening and treatment of precancer. Each month, death can occur from cervical cancer or non-cervical cancer causes (ie, background mortality). Disease progression and regression, clinical events, and economic outcomes are tracked over the lifetime of each woman and aggregated over the cohort of one million women.

![Model schematic. Screening, diagnosis and treatment of precancer or cancer are determined by screening strategy (this figure has been reproduced by permission of Oxford University Press, [https://global.oup.com/academic/rights/permissions/autperm/?cc=us&lang=en&)](https://global.oup.com/academic/rights/permissions/autperm/?cc=us&lang=en&). CIN2, cervical intraepithelial neoplasia grade 2; CIN3, cervical intraepithelial neoplasia grade 3.](bmjopen-2017-020484f01){#F1}

We used a likelihood-based approach (described in detail elsewhere) to calibrate the natural history model to epidemiological data from Uganda.[@R10] Data on HPV incidence,[@R17] progression and clearance,[@R18] precancer progression[@R19] and regression,[@R20] and cancer progression and mortality[@R21] from longitudinal studies were used to establish baseline input values. Age-specific and type-specific HPV incidence, naturally acquired immunity following HPV infection, and progression and regression of precancer were identified as parameters with a high degree of uncertainty, and were thus selected for calibration. We set a range of plausible bounds for these uncertain model parameters and then randomly sampled from a uniform distribution across this range of values.[@R10] The range of plausible bounds that was sampled from for each variable is shown in the technical online [supplementary appendix](#SP1){ref-type="supplementary-material"}. Each model simulation selected one random value within the bounds for each uncertain parameter, creating a unique natural history input parameter set. By summing the log-likelihood of model-projected outcomes for each input parameter set relative to the epidemiological data on age-specific high-risk HPV prevalence and age-specific cancer incidence from Uganda,[@R10] we computed a goodness-of-fit score. We selected the 50 top-fitting input parameter sets to use in this analysis. Results are reported as the mean and range across the top 50 parameter sets, and ICERs are reported as the ratio of the mean costs divided by the mean effects of one strategy versus another across sets.[@R25]
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Screening strategies {#s2d}
--------------------

We considered the following screening strategies ([figure 2](#F2){ref-type="fig"}): (1) self-collected HPV testing at home or work followed by VIA triage for HPV-positive women, with cryotherapy for eligible women who were positive on both tests (HPV-VIA); (2) self-collected HPV testing at home or work followed by cryotherapy for all eligible HPV-positive women (HPV screen-and-treat strategy, HPV-ST) and (3) VIA at the clinic followed by cryotherapy for eligible women (VIA). While HPV-ST was not evaluated in the ASPIRE study, we considered this strategy over concerns that VIA triage of HPV-positive women may miss some precancer. The HPV-ST strategy is identical to the HPV-VIA strategy, except we assumed that all eligible HPV-positive women were referred to cryotherapy at Kisenyi clinic (regardless of visual inspection findings). In all three strategies, women who were not deemed eligible for cryotherapy at the Kisenyi clinic (based on visual inspection in all strategies) were referred to a tertiary care centre for further evaluation with colposcopy.

![Pathways of care. This figure depicts the HPV-VIA and VIA screening strategies. The HPV-ST strategy is identical to HPV-VIA, except all HPV-positive women are offered cryotherapy (if eligible) or are referred to a tertiary care centre (if ineligible). ST, screen-and-treat strategy; VIA, visual inspection with acetic acid.](bmjopen-2017-020484f02){#F2}

We evaluated screening once in a lifetime at age 39 to represent the average age and number of screens in the ASPIRE trial. In keeping with WHO guidelines to prioritise screening among women aged 30--49 years,[@R5] we also evaluated scenarios of screening three times at ages 30, 40 and 50 years and screening every 5 years at ages 30, 35, 40, 45 and 50 years. For the base case analysis, we assumed screening coverage of 70%. [Table 1](#T1){ref-type="table"} displays model inputs on screening uptake, compliance, test performance, treatment eligibility and treatment effectiveness. Values for screening uptake, the proportion of women who were reachable by phone for delivery of results, and compliance with Kisenyi Health Centre visits and cryotherapy were informed by the ASPIRE trial. Compliance and uptake for the HPV-ST strategy was assumed to be identical to the HPV-VIA arm as the structure of the screening pathway was assumed to be the same. HPV test performance characteristics with self-collection were informed by a care HPV demonstration project in Uganda.[@R6]

###### 

Baseline values and ranges for sensitivity analysis\*

  ---------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                         Baseline value                        Sensitivity analysis
  -------------------------------------------------------------------------------------- ------------------------------------- ----------------------
  Screening and treatment parameters                                                                                           

  Screening age(s)[@R5]                                                                  1x: age 39 years;\                    --
                                                                                         3x: ages 30, 40 and 50 years;\        
                                                                                         5x: ages 30, 35, 40,45 and 50 years   

  Population coverage                                                                    70.0%                                 40.0%--100%

  Uptake of self-collected HPV testing[@R11]                                             99.2%                                 --

  Uptake of VIA[@R11]                                                                    48.4%                                 --

  Proportion of women successfully contacted over phone with HPV test results[@R11]      63.0%                                 46.6%--90.0%

  Proportion of contacted HPV-positive women attending the clinic[@R11]                  97.1%                                 --

  Compliance for all other visits                                                        85.0%                                 0%; 40.0%

  Proportion of eligible women receiving cryotherapy following positive VIA[@R11]        78.6%                                 --

  Proportion of eligible women receiving cryotherapy following positive HPV test[@R11]   78.6%                                 --

  Proportion of women receiving treatment following colposcopy                           85.0%                                 

  Proportion of women who refuse cryotherapy then return at a later date[@R11]           0.0%                                  52.0%

  Test sensitivity/specificity for CIN2+                                                                                       

   HPV (self-collected)[@R6]                                                             77.0%/82.0%                           100%/100%

   VIA (primary screen)[@R6]                                                             73.6%/66.6%                           41.4%/94.5%

   VIA (triage test)[@R6]                                                                73.6%/66.6%                           36.4%--81.9%/\
                                                                                                                               66.6%--94.5%

  Test sensitivity/specificity for CIN1+, colposcopy[@R10]‡                              95.0%/51.0%                           --

  Eligibility for cryotherapy[@R34]                                                                                            

   No lesion                                                                             90.0%                                 72.2%--92.7%

   CIN2                                                                                  85.0%                                 42.2%--87.7%

   CIN3                                                                                  75.0%                                 42.2%--82.7%

   Cancer                                                                                10.0%                                 --

  Cryotherapy effectiveness at the clinic[@R38]                                          81.0%                                 70.0%--92.0%

  Cryotherapy effectiveness at the referral centre[@R44]                                 81.0%                                 70.0%--92.0 %

  Proportion of women who retain HPV infection following cryotherapy                     10.0%                                 --

  Cost parameters, women's time costs                                                                                          

   Women's time cost, per hour[@R30]                                                     US\$0.46                              --

   Self-collection of HPV sample                                                         US\$0.19                              --

   VIA screen                                                                            US\$1.38                              --

   Cryotherapy with no VIA (Kisenyi)                                                     US\$1.46                              

   Extra time for cryotherapy post-VIA                                                   US\$0.03                              --

   Colposcopy and biopsy                                                                 US\$2.76                              --

   Cryotherapy (Mulago National Referral Hospital)                                       US\$2.76                              --

  Cost parameters, programmatic costs†                                                                                         

   Programmatic cost per women screened                                                  US\$6.58                              --

  Cost parameters, direct medical costs§                                                                                       

   Self-collected HPV test[@R10]                                                         US\$12.73                             US\$34.08

   VIA                                                                                   US\$14.64                             --

   Cost per cryotherapy[@R10]                                                            US\$5.85                              US\$27.37

   Cost per colposcopy and biopsy[@R11]                                                  US\$52.25                             --

  Treatment of cancer[@R27]                                                                                                    

   Local                                                                                 US\$627                               US\$2328

   Regional                                                                              US\$797                               US\$2332

   Distant                                                                               US\$797                               US\$3953
  ---------------------------------------------------------------------------------------------------------------------------------------------------

1x: screening at age 39; 3x: screening at ages 30, 40 and 50; 5x: screening at ages 30, 35, 40, 45 and 50.

\*Costs are described in greater detail in the technical online [supplementary appendix](#SP1){ref-type="supplementary-material"}.

†Programmatic costs include costs for a programme assistant and a community preparedness campaign.

‡As CIN1 is not actually a health state in the model, colposcopy performance is based on the health state of no lesion, HPV infection, CIN2 or CIN3. A treatment threshold for CIN1 was estimated by weighting colposcopy sensitivity for HPV+ women based on the prevalence of CIN1 among HPV+ women in the Uganda START-UP study.

§Base case direct medical costs of HPV testing and cryotherapy were informed by START-UP[@R10] due to the ASPIRE trial using HPV genotyping technology at an additional expense (this would not be performed in a non-research setting) and the number of assumptions required for cryotherapy cost amortisation.

ASPIRE, Advances in Screening and Prevention of Reproductive Cancers; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; VIA, visual inspection with acetic acid.

Cost data {#s2e}
---------

Cost data and time estimates are described extensively in the technical online [supplementary appendix](#SP1){ref-type="supplementary-material"} and presented in [table 1](#T1){ref-type="table"}. Costing was done from a societal perspective so that policy-makers can evaluate the impact on all stakeholders.[@R26] Costs included direct medical costs (including CHW salary, provider wages, supply costs, sample transport costs, laboratory costs and equipment costs), women's time costs and programmatic costs. Briefly, cost data and time estimates were derived from a review of ASPIRE budget sheets, receipts, grant reconciliation sheets and consultation with researchers involved in the trial. When applicable, costs attributable to NGCT sampling were excluded. In several cases, ASPIRE cost data were not available and we instead used costs from other studies. HPV self-collection test cost, supplies, HPV laboratory costs and cryotherapy equipment costs were informed by the PATH START-UP demonstration project in Uganda.[@R6] Cancer treatment costs were derived from Campos *et al*.[@R27] Costs were collected in US\$, Canadian dollars and Ugandan shillings (UGX). All costs are presented in 2014 US\$. If costs were collected in 2014, exchange rates were applied to convert costs to 2014 US\$.[@R28] If costs were collected in a different year, we converted the currency to UGX, applied Ugandan GDP deflators to account for inflation,[@R29] and then converted the cost to US\$. Equipment costs were annualised to represent the duration of their use assuming a 3% interest rate.

Women's time spent travelling, waiting for and receiving care was valued using an average hourly wage for women enrolled in the trial. This was calculated by applying ASPIRE demographic survey data on education levels to Ugandan Ministry of Gender, Labour and Social Development data on average wages based on education level.[@R30] Time estimates were informed by the ASPIRE demographic survey and consultation with researchers and clinicians who took part in the ASPIRE trial. Other societal costs, such as lost future productivity and impact on education have not been included due to a lack of data to objectively estimate these costs.

Programmatic costs were derived from the ASPIRE trial. These costs included a programme assistant and a community preparedness campaign that occurred in the month leading up to the trial to educate women on HPV and cervical cancer.

Further details on cost data and assumptions are provided in the technical online [supplementary appendix](#SP1){ref-type="supplementary-material"}.

Sensitivity and scenario analyses {#s2f}
---------------------------------

To explore uncertainty around model inputs, we performed univariate and multivariate sensitivity analyses under the scenario of once in a lifetime screening at age 39 on the following variables: VIA primary screening test sensitivity/specificity,[@R31] VIA triage test sensitivity,[@R32] cryotherapy eligibility,[@R11] HPV test direct medical costs,[@R11] cryotherapy treatment costs,[@R11] cancer treatment costs,[@R37] cryotherapy efficacy,[@R38] the proportion of women who were reachable by phone for results delivery,[@R11] midwife costs per VIA, CHW costs, loss to follow-up for referral centre visits, screening coverage, proportion of women who return for cryotherapy after initially refusing, colposcopy costs and discount rates.

Additionally, we performed the following scenario analyses: we evaluated only HPV-VIA and VIA once, three times, and five times per lifetime, ignoring the HPV-ST strategy that was inferred from ASPIRE results; we assumed all precancer treatment at referral centres was loop electrosurgical excisional procedure (LEEP) by increasing the treatment efficacy to 96.4%[@R39] and the direct medical costs to US\$86.70 per LEEP (in the base case, only cryotherapy was available)[@R9]; and we leveraged data from a study demonstrating that door-to-door follow-up with CHWs in South Africa increased adherence to cervical cancer screening visits and increased the CHW cost per women by US\$2.68 to increase compliance in all three strategies.[@R40]

Results {#s3}
=======

Reduction in cervical cancer risk {#s3a}
---------------------------------

The relative and absolute reductions in cancer risk for HPV-ST, HPV-VIA and VIA once per lifetime, three times per lifetime and five times per lifetime compared with no screening are presented in [table 2](#T2){ref-type="table"}. At every screening frequency, HPV-ST led to the largest reduction in lifetime risk of cervical cancer, followed by HPV-VIA, and then VIA. Cancer risk reduction increased with the number of lifetime screens for all strategies. Screening every 5 years between ages 30 and 50 years reduced cancer risk by 42.8%, 26.1% and 24.2% for HPV-ST, HPV-VIA and VIA, respectively.

###### 

Base case results\*

                 ICER (US\$/YLS)   Relative cervical cancer risk reduction†   Absolute lifetime cervical cancer risk
  -------------- ----------------- ------------------------------------------ ----------------------------------------
  No screening   --                --                                         4.2% (3.8%--4.7%)
  HPV-ST 1x      130 (110--150)    15.0% (13.3%--16.6%)                       3.5% (3.2%--4.0%)
  VIA 1x         DOM               7.2% (6.3%--8.2%)                          3.9% (3.5%--4.3%)
  HPV-VIA 1x     DOM               7.6% (6.7%--8.7%)                          3.9% (3.5%--4.3%)
  HPV-ST 3x      240 (210--280)    33.0% (30.6%--35.5%)                       2.8% (2.4%--3.1%)
  VIA 3x         DOM               16.9% (15.4%--18.8%)                       3.5% (3.1%--3.9%)
  HPV-VIA 3x     DOM               18.4% (16.7%--20.5%)                       3.4% (3.0%--3.8%)
  HPV-ST 5x      470 (410--550)    42.8% (39.8%--45.6%)                       2.4% (2.1%--2.7%)
  VIA 5x         DOM               24.2% (22.0%--26.4%)                       3.2% (2.8%--3.5%)
  HPV-VIA 5x     DOM               26.1% (23.9%--28.5%)                       3.1% (2.7%--3.4%)

The base case analysis compares all three screening strategies at all three screening frequencies. 1x: screening at age 39 years; 3x=screening at ages 30, 40 and 50 years; 5x=screening at ages 30, 35, 40, 45 and 50 years; DOM: more costly and less effective or having a higher ICER than equally or more effective strategies; ICER: expressed in 2014 US\$ per YLS.

\*Values indicate the mean results across the top 50 best fitting parameter sets. The minimum and maximum values across these 50 parameter sets are shown in parentheses.

†Relative reduction in lifetime risk of cervical cancer is compared with no screening.

DOM, dominated strategy; HPV, human papillomavirus; HPV-ST, community-based HPV self-collection with clinic-based cryotherapy of eligible HPV+ women; HPV-VIA, community-based HPV self-collection with clinic-based VIA triage and immediate treatment of eligible VIA+ women; ICER, incremental cost- effectiveness ratio; ST, screen-and-treat strategy; VIA, visual inspection with acetic acid; VIA, clinic-based VIA with immediate treatment of eligible VIA+ women; YLS, years of life saved.

Cost-effectiveness {#s3b}
------------------

Results from cost-effectiveness analysis are presented in [table 2](#T2){ref-type="table"} and [figure 3](#F3){ref-type="fig"}. HPV-ST was the least costly and most effective strategy at all screening frequencies, dominating HPV-VIA and VIA. The ICERs of HPV-ST once, three times and five times per lifetime were US\$130 per YLS, US\$240 per YLS and US\$470 per YLS, respectively. HPV-ST would therefore be very cost-effective based on a willingness to pay threshold of Uganda's 2014 GDP per capita (US\$730).[@R14]

![Cost-effectiveness results: base case analysis. ICERs (expressed in 2014 US\$ per year of life saved) are in parentheses for non-dominated strategies. 1x: screening at age 39 tears (yellow); 3x: screening at ages 30, 40 and 50 years (green); 5x: screening at ages 30, 35, 40, 45 and 50 years (orange); HPV-ST: HPV screen and treat (diamonds); HPV-VIA: HPV with VIA triage (squares); VIA: VIA screen and treat (triangles). The black line denotes the efficiency frontier. Any strategy lying to the right of the efficiency frontier is a dominated strategy because it is more costly and less effective or has a higher ICER than equally or more effective strategies. ICER, incremental cost-effectiveness ratio; ST, screen-and-treat strategy; VIA, visual inspection with acetic acid; YLS, year of life saved.](bmjopen-2017-020484f03){#F3}

Sensitivity and scenario analysis {#s3c}
---------------------------------

Results from sensitivity and scenario analyses are described in [tables 3 and 4](#T3 T4){ref-type="table"}. The finding that the HPV-ST strategy was the most effective was robust as we varied VIA primary screening test performance, VIA triage test performance, cryotherapy eligibility, cryotherapy efficacy, telephone compliance, loss to follow-up for tertiary care centre visits, screening coverage, proportion of women who return for cryotherapy after initially refusing, direct medical costs of HPV testing and VIA, and discount rates. HPV-VIA was more effective than VIA in all sensitivity analyses conducted except when telephone contact rates of HPV-positive women were reduced to 46.6% in the HPV-VIA strategy or the sensitivity of the VIA triage test was 36.4%. The effectiveness of different strategies was most sensitive to changes in screening coverage and compliance variables. For example, increasing screening coverage to 100% led to an increase in the relative reduction of lifetime cervical cancer risk from 15.0% to 21.6% (HPV-ST), while increasing telephone contact rates to 90% increased relative reduction of lifetime cervical cancer risk from 15.0% to 21.5% (HPV-ST).

###### 

Results: sensitivity analyses, once in a lifetime screening\*

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                  Variables                   Relative reduction in lifetime cervical cancer risk   ICER (US\$/YLS)                            
  --------------------------------------------------------------- --------------------------- ----------------------------------------------------- ----------------- ------- ------- -------- -------
  VIA performance (screening and triage test)[@R31]               41.4%/94.5%                 3.9%                                                  15.0%             3.7%    DOM     \$130    DOM

  VIA performance (triage test only)[@R32]                        81.9%/66.6%                 8.3%                                                  15.0%             7.2%    DOM     \$130    DOM

  36.4%/90.4%                                                     3.6%                        15.0%                                                 7.2%              DOM     \$130   DOM      

  Cryotherapy eligibility (no lesion/CIN2\                        72.2%/58.1%/\               7.1%                                                  13.3%             6.9%    DOM     \$160    DOM
  /CIN3/cancer)[@R11]                                             58.1%/10.0%                                                                                                                  

  79.6%/42.2%/\                                                   7.2%                        13.2%                                                 6.8%              DOM     \$160   DOM      
  42.2%/10.0%                                                                                                                                                                                  

  92.7%/87.7%/\                                                   7.6%                        15.2%                                                 7.2%              DOM     \$130   DOM      
  82.7%/10.0%                                                                                                                                                                                  

  79.8%/74.8%/\                                                   7.5%                        14.4%                                                 7.1%              DOM     \$150   DOM      
  69.8%/10.0%                                                                                                                                                                                  

  HPV test cost                                                   US\$28.03                   7.6%                                                  15.0%             7.2%    DOM     \$310    \$300

  Cryotherapy costs                                               US\$27.37                   7.6%                                                  15.0%             7.2%    DOM     \$160    DOM

  Cancer costs (local/regional/distant)[@R37]                     US\$2327\                   7.6%                                                  15.0%             7.2%    DOM     \$50     DOM
                                                                  /US\$2331/\                                                                                                                  
                                                                  US\$3952                                                                                                                     

  Direct medical costs (HPV/VIA)                                  US\$13.98/US\$13.40\        7.6%\                                                 15.0%\            7.2%\   DOM\    \$150\   DOM\
                                                                  US\$12.73/US\$9.66\         7.6%\                                                 15.0%\            7.2%\   DOM\    \$130\   DOM\
                                                                  US\$13.98/US\$8.42          7.6%                                                  15.0%             7.2%    DOM     \$150    DOM

  Cryotherapy effectiveness[@R38]                                 92%                         8.7%                                                  17.0%             8.1%    DOM     \$120    DOM

  70%                                                             6.6%                        12.8%                                                 6.1%              DOM     \$160   DOM      

  Proportion of women successfully\                               46.6%                       5.6%                                                  11.0%             7.2%    DOM     \$190    DOM
  contacted over phone with HPV test results                                                                                                                                                   

  75.0%                                                           9.1%                        17.8%                                                 7.2%              DOM     \$110   DOM      

  90.0%                                                           11.0%                       21.5%                                                 7.2%              DOM     \$90    DOM      

  Loss to follow-up‡                                              0%                          7.9%                                                  15.5%             7.5%    DOM     \$130    DOM

  40%                                                             7.2%                        14.4%                                                 6.8%              DOM     \$150   DOM      

  Screening coverage                                              100%                        10.9%                                                 21.6%             10.2%   DOM     \$130    DOM

  85%                                                             9.3%                        18.3%                                                 8.7%              DOM     \$130   DOM      

  55%                                                             6.0%                        11.7%                                                 5.6%              DOM     \$130   DOM      

  40%                                                             4.4%                        8.6%                                                  4.1%              DOM     \$130   DOM      

  HPV test performance (sensitivity/specificity)                  100%/100% to detect hrHPV   8.7%                                                  17.3%             7.2%    DOM     \$120    DOM

  Cryotherapy compliance[@R37]†                                   52%                         8.5%                                                  --                8.1%    \$250   --       DOM

  Colposcopy transport cost                                       US\$0.50                    7.6%                                                  15.0%             7.2%    DOM     \$140    DOM

  Discount rate                                                   0%                          7.6%                                                  15.0%             7.2%    DOM     \$50     DOM

  5%                                                              7.6%                        15.0%                                                 7.2%              DOM     \$230   DOM      

  Scenario---CHWs to reduce LTFU to women attending clinic for\   --                          10.4%                                                 20.3%             11.6%   DOM     \$110    DOM
  VIA or cryotherapy[@R40]                                                                                                                                                                     

  Scenario---100% LEEP following histological confirmation        --                          7.8%                                                  15.3%             7.4%    DOM     \$140    DOM
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Relative reduction in lifetime cancer risk is relative to no screening; incremental cost-effectiveness ratios are presented in 2014 US\$; DOM: more costly or higher ICER than equally or more effective strategies.

\*Sensitivity analyses are described in detail in the technical online [supplementary appendix](#SP1){ref-type="supplementary-material"}.

†The model was not equipped to handle a change in this variable in the HPV-ST arm.

‡This variable refers only to loss to follow up for visits to the referral centre for colposcopy or follow-up of cryotherapy ineligible lesions.

CHW, community health worker; CIN2, cervical intraepithelial neoplasia grade 2; DOM, dominated strategy; ICER, incremental cost-effectiveness ratio; LEEP, loop electrosurgical excisional procedure; LTFU, loss to follow-up; ST, screen-and-treat strategy; VIA, visual inspection with acetic acid; YLS; year of life saved.

###### 

Sensitivity analysis: cost-effectiveness of HPV-VIA versus VIA\*

                 Discounted cost per woman   Discounted life expectancy† (years)   ICER (US\$/YLS)   Relative cervical cancer risk reduction (%)   Absolute lifetime cervical cancer risk (%)
  -------------- --------------------------- ------------------------------------- ----------------- --------------------------------------------- --------------------------------------------
  No screening   US\$9.19 (8.14--10.45)      26.2445 (26.2134--26.2737)            --                --                                            4.2 (3.8--4.7)
  VIA 1x         US\$13.88 (12.84--15.06)    26.2602 (26.2315--26.2883)            DOM               7.2 (6.3--8.2)                                3.9 (3.5--4.3)
  HPV-VIA 1x     US\$13.99 (12.90--15.12)    26.2618 (26.2334--26.2898)            280 (230--320)    7.6 (6.7--8.7)                                3.9 (3.5--4.3)
  VIA 3x         US\$23.77 (22.77--24.83)    26.2827 (26.2575--26.3086)            DOM               16.9 (15.4--18.8)                             3.5 (3.1--3.9)
  HPV-VIA 3x     US\$23.94 (22.84--25.10)    26.2860 (26.2612--26.3117)            410 (360--480)    18.4 (16.7--20.5)                             3.4 (3.0--3.8)
  VIA 5x         US\$33.52 (32.58--34.49)    26.2993 (26.2763--26.3235)            DOM               24.2 (22.0--26.4)                             3.2 (2.8--3.5)
  HPV-VIA 5x     US\$33.85 (32.72--34.85)    26.3033 (26.2812--26.3272)            570 (490--640)    26.1 (23.9--28.5)                             3.1 (2.7--3.4)

1x: screening at age 39 years; 3x: screening at ages 30, 40 and 50 years; 5x: screening at ages 30, 35, 40, 45 and 50 years; HPV-VIA: HPV with VIA triage; VIA: VIA screen and treat. DOM: more costly or higher ICER than equally or more effective strategies; incremental cost-effectiveness ratio (ICER): expressed in 2014 US\$ per year of life saved (YLS); relative cancer reduction is the lifetime reduction relative to no screening.

\*Values indicate the mean results across the top 50 top-fitting parameter sets. The minimum and maximum values across these 50 parameter sets are shown in parentheses.

†Discounted life expectancy is after age 9, the age at which women enter the model.

DOM, dominated strategy; ICER, incremental cost- effectiveness ratio; VIA, visual inspection with acetic acid; YLS, year of life saved.

The HPV-ST strategy was very cost-effective and dominated HPV-VIA and VIA in all sensitivity analyses, except when HPV test costs were more than quadrupled, in which case VIA was no longer a dominated strategy and had an ICER of US\$300 per YLS. The ICER for HPV-ST fell below US\$50 per YLS when cancer costs increased more than threefold and when there was no discounting of future costs and life years, and only increased above US\$200 per YLS when HPV test costs increased or the discount rate was 5% (base case: US\$130 per YLS). Scenario analyses demonstrated that using CHWs for in-person follow-up could be a very cost-effective approach to increase retention to screening pathways, while using LEEP instead of cryotherapy had little impact on both cancer reductions and ICERs compared with the base case.

When we assumed only HPV-VIA and VIA were available ([table 4](#T4){ref-type="table"}), as in the ASPIRE study, HPV-VIA dominated VIA at all screening frequencies and would be very cost-effective with an ICER of US\$570/YLS when performed five times per lifetime.

Patient and public involvement {#s3d}
------------------------------

There was no patient or public involvement in this study as it was based on mathematical modelling. However, the ASPIRE trial held multiple community engagement and education workshops to describe the interventions and provide broader education about HPV and cervical cancer in Uganda. The CHWs who were hired in the trial were members of the local community and were trained on the trial protocol and procedures. While all individual screening results were communicated with trial participants, there was no formal process for relaying the trial results to the participants. Trial results were disseminated to the local study team.

Discussion {#s4}
==========

We evaluated the cost-effectiveness of a novel self-collected HPV testing strategy using uptake, follow-up and cost data from the ASPIRE trial in Uganda. To our knowledge, this is the first study to use trial data to evaluate the cost-effectiveness of a delivery model relying on CHWs to offer home-based HPV self-collection. We found that screening with self-collected HPV testing followed by cryotherapy for eligible HPV-positive women (HPV-ST) would be very cost-effective in Uganda and could reduce the risk of cervical cancer by 15.0% if offered once in a lifetime at age 39 or up to 42.8% if offered every 5 years between ages 30 and 50 years. HPV testing with VIA triage of HPV-positive women to determine treatment and VIA alone were both more costly and less effective than HPV-ST, and thus not efficient strategies.

Previous cost-effectiveness studies evaluating self-collected HPV testing have demonstrated that self-collection can be a cost-effective screening method if it achieves higher levels of population coverage than provider-collected HPV testing.[@R4] For instance, in weighing the trade-off between test sensitivity and higher screening coverage, Campos *et al* found that a 20% loss in test sensitivity due to self-collection can be offset by a 20% gain in screening coverage.[@R8] While the ASPIRE trial compared HPV self-collection to VIA, the results still demonstrate the importance of uptake rates in determining cost-effectiveness. In the ASPIRE trial, 248 out of 250 women agreed to self-collect, while 121 out of 250 women attended the clinic for VIA. This enhanced uptake of HPV self-collection, when combined with the higher sensitivity to detect precancer of self-collected HPV testing (compared with VIA), rendered the HPV-ST screening strategy the most effective and cost-effective screening strategy in this analysis. These findings provide evidence that real-world increases in screening coverage due to door-to-door self-collection opportunities may translate into improved health and cost-effectiveness outcomes, and were robust to numerous sensitivity analyses.

The ASPIRE self-collection strategy could be further improved on if more HPV-positive women were successfully contacted with their results. In the ASPIRE trial, with a protocol of three phone attempts to contact women with their results, 34 of the 54 women who were HPV-positive could not be contacted. Of the HPV-positive women who were successfully contacted, 33 out of the 34 came in to Kisenyi clinic for follow-up. Strategies to improve delivery of test results should be explored. Sensitivity analysis showed that increasing delivery of results would further decrease cancer risk, and that having CHWs do in-person follow-up could be a cost-effective strategy to improve management for screen-positive women.[@R40] Alternatively, other models of community-based self-collection have been proposed. Campos *et al* showed how a community mobilisation campaign with group self-collection is a cost-effective alternative to provider collection if it increases population coverage.[@R9] Future research should compare different models of offering self-collection and consider setting-specific factors that could make certain delivery methods more efficient.

An important finding is that HPV testing is more effective when there is no VIA triage before cryotherapy, a result that contradicts current WHO recommendations for countries with enough resources to provide a sequence of tests.[@R5] This is due to the high false negative rate of VIA, the implications of which are amplified when the false negatives are in a high-risk group (ie, women already known to be HPV-positive). Our base case analysis assumed that VIA as a triage test performed similarly to VIA in a general screening population, detecting 73.6% of CIN2+.[@R6] Other studies in Africa looking at VIA sensitivity as a triage test have showed large variability, with sensitivities ranging from 25.0% to 81.9%.[@R32] These findings suggest that future programmes should consider incorporating HPV-ST. However, this will lead to an increase in the number of cryotherapy procedures in women who may not have or may not develop precancer. While our results demonstrated that ST would be cost-effective, LMICs will likely face human resource and capacity constraints and may be overburdened by the high number of cryotherapy procedures. Moreover, while cryotherapy has been shown to be safe and acceptable,[@R38] concern has arisen that there could be an increased risk of HIV incidence following cryotherapy.[@R42] This is of particular concern in settings with high HIV prevalence. Better triage tests are needed to improve identification of women at high risk of developing cervical cancer while reducing the number of treatments that are required of overburdened health systems.

Several limitations of this study should be noted. Our costing of the ASPIRE trial was hindered by the fact that the trial was not initially designed to evaluate cost-effectiveness, and thus all cost estimates are retrospective. Therefore, the trial may not reflect real-world (as opposed to study) conditions, and thus the amount paid for equipment, supplies and labour does not necessarily reflect actual programmatic costs. Cancer treatment costs had to be inferred from other studies. In a few cases, we used cost data from the PATH START-UP demonstration project to more accurately reflect real-world costs, as detailed in the technical online [supplementary appendix](#SP1){ref-type="supplementary-material"}. The base case assumption that VIA was more costly than HPV testing is unusual, and attributable to VIA having a provider cost (where HPV testing was self-collected) and requiring more CHW time to encourage compliance. Still, sensitivity analyses revealed that HPV-ST remained the dominant screening strategy even as the relative cost of HPV testing versus VIA was varied considerably. Concern has been raised that using GDP per capita as a threshold for cost-effectiveness may not be affordable in LMICs, however, even with a threshold of 50% of GDP per capita our analysis shows that HPV-ST one and three times per lifetime would be very cost-effective.[@R43] Furthermore, the costing for this study was based on a trial involving 250 women in each arm, which may not be sufficient to capture programmatic economies of scale.

In addition to limitations on costing data, the trial setting limited the scope of this cost-effectiveness analysis. It is unclear how real-world human resource constraints might affect the cost-effectiveness of the different screening strategies through impact on women's waiting time in typical primary care settings. Furthermore, decision-makers will need to assess where limited healthcare provider time is best spent. It is of note that all the women in this study had access to a mobile phone. This may not be the case in rural and remote areas of Uganda, so novel screening approaches may need to be developed that would be more suitable for these locations.

While it was not a stated objective of this study to evaluate the cost-effectiveness of NGCT screening, this was an integral part of the ASPIRE trial due to the hypothesis that efficiency gains could be achieved by bundling health interventions with overlapping infrastructure needs. Moving forward, developing models that can evaluate the integrated delivery of primary care services will be critical to assess the wider impacts of new healthcare delivery methods in low-resource settings, as well as to capture potential synergies associated with packaging interventions.

In 2012, over 230 000 women in LMICs died from cervical cancer, approximately 2200 of whom were from Uganda.[@R2] This study demonstrates that there are very cost-effective options that could significantly reduce morbidity and mortality attributable to cervical cancer. Implementation studies on a larger scale---that would assess the effectiveness and cost-effectiveness of community-based screening in the context of the Ugandan health system---are warranted. Such studies will provide lessons for nascent screening programmes in low-resource settings with a high burden of cervical cancer.
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